Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours

BACKGROUND: Despite substantial improvements in childhood cancer survival, drug resistance remains problematic for several paediatric tumour types. The urgent need to access novel agents to treat drug-resistant disease should be expedited by pre-clinical evaluation of paediatric tumour models during...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, D, Holt, S V, Brookes, K E, Klymenko, T, Adamski, J K, Hogg, A, Estlin, E J, Ward, T, Dive, C, Makin, G W J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713707/
https://www.ncbi.nlm.nih.gov/pubmed/19491903
http://dx.doi.org/10.1038/sj.bjc.6605100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713707/
https://www.ncbi.nlm.nih.gov/pubmed/19491903
http://dx.doi.org/10.1038/sj.bjc.6605100

Ejemplares similares